GALECTIN THERAPEUTICS INC (GALT) — insider trading
Health Care · NASDAQ
GALECTIN THERAPEUTICS INC (GALT) has 31 reported SEC Form 4 insider transactions in our data, including 1 open-market purchase and 8 open-market sales among the most recent 31 (latest 2026-07-14).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-14 | Jamil Khurram | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 16,250 | $0.00 | $0 | Form 4 |
| 2026-07-14 | Jamil Khurram | Officer (Chief Medical Officer) | Open-market sale | 16,250 | $5.13 | $83.3K | Form 4 |
| 2026-07-14 | Jamil Khurram | Officer (Chief Medical Officer) | Option exercise / conversion | 16,250 | $3.04 | $49.4K | Form 4 |
| 2026-06-29 | Jamil Khurram | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 47,467 | $0.00 | $0 | Form 4 |
| 2026-06-29 | Jamil Khurram | Officer (Chief Medical Officer) | Open-market sale | 47,467 | $5.04 | $239.2K | Form 4 |
| 2026-06-29 | Jamil Khurram | Officer (Chief Medical Officer) | Option exercise / conversion | 47,467 | $2.50 | $118.7K | Form 4 |
| 2026-06-29 | Shlevin Harold H. | Director | Option exercise / conversion (derivative) | 22,268 | $0.00 | $0 | Form 4 |
| 2026-06-29 | Shlevin Harold H. | Director | Open-market sale | 22,268 | $5.04 | $112.2K | Form 4 |
| 2026-06-29 | Shlevin Harold H. | Director | Option exercise / conversion | 22,268 | $1.23 | $27.4K | Form 4 |
| 2026-06-26 | Jamil Khurram | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 2,533 | $0.00 | $0 | Form 4 |
| 2026-06-26 | Jamil Khurram | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 2,037 | $0.00 | $0 | Form 4 |
| 2026-06-26 | Jamil Khurram | Officer (Chief Medical Officer) | Open-market sale | 2,533 | $5.00 | $12.7K | Form 4 |
| 2026-06-26 | Jamil Khurram | Officer (Chief Medical Officer) | Option exercise / conversion | 2,533 | $2.50 | $6.3K | Form 4 |
| 2026-06-26 | Jamil Khurram | Officer (Chief Medical Officer) | Open-market sale | 2,037 | $5.00 | $10.2K | Form 4 |
| 2026-06-26 | Jamil Khurram | Officer (Chief Medical Officer) | Option exercise / conversion | 2,037 | $2.20 | $4.5K | Form 4 |
| 2026-06-26 | Shlevin Harold H. | Director | Option exercise / conversion (derivative) | 7,732 | $0.00 | $0 | Form 4 |
| 2026-06-26 | Shlevin Harold H. | Director | Open-market sale | 7,732 | $5.00 | $38.7K | Form 4 |
| 2026-06-26 | Shlevin Harold H. | Director | Option exercise / conversion | 7,732 | $1.23 | $9.5K | Form 4 |
| 2026-06-23 | Jamil Khurram | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 7,557 | $0.00 | $0 | Form 4 |
| 2026-06-23 | Jamil Khurram | Officer (Chief Medical Officer) | Open-market sale | 7,557 | $3.14 | $23.7K | Form 4 |
| 2026-06-23 | Jamil Khurram | Officer (Chief Medical Officer) | Option exercise / conversion | 7,557 | $1.23 | $9.3K | Form 4 |
| 2026-05-26 | Jamil Khurram | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 568 | $0.00 | $0 | Form 4 |
| 2026-05-26 | Jamil Khurram | Officer (Chief Medical Officer) | Open-market sale | 568 | $3.10 | $1.8K | Form 4 |
| 2026-05-26 | Jamil Khurram | Officer (Chief Medical Officer) | Option exercise / conversion | 568 | $1.23 | $699 | Form 4 |
| 2026-03-12 | Brem Henry | Director | Grant / award / vesting (derivative) | 60,000 | $0.00 | $0 | Form 4 |
| 2026-02-06 | ELDRED KARY | Director | Open-market purchase | 300 | $2.70 | $810 | Form 4 |
| 2026-01-16 | LEWIS JOEL | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 91,000 | $0.00 | $0 | Form 4/A |
| 2026-01-16 | Jamil Khurram | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 100,000 | $0.00 | $0 | Form 4 |
| 2026-01-16 | Jamil Khurram | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 65,000 | $0.00 | $0 | Form 4 |
| 2026-01-16 | Zordani Richard A. Jr. | Director | Grant / award / vesting (derivative) | 60,000 | $0.00 | $0 | Form 4 |
| 2026-01-16 | CARSON BENJAMIN SR | Director | Grant / award / vesting (derivative) | 60,000 | $0.00 | $0 | Form 4 |
Ask the chat about GALT's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: GALECTIN THERAPEUTICS INC (GALT).
Last updated 2026-07-14 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.